Fri.Jan 19, 2024

article thumbnail

Work Pressure During COVID-19 Pandemic Increased Problematic Substance Use Among First Responders

Drug Topics

Problematic substance use was highest among firefighters, followed by emergency medical technicians, and police officers.

220
220
article thumbnail

All it Takes is a Conversation: Deprescribing Benzodiazepines in Older Adults

Pharmacy Times

Benzodiazepines have proven effective in managing anxiety and insomnia, but they heighten risk of falls, cognitive impairment, functional decline, and mortality among older adults.

156
156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data

STAT

Scientists at Dana-Farber Cancer Institute, one of the nation’s leading cancer research and treatment centers, are “moving to” retract one paper and correct others amid an expanding investigation of data manipulation, officials told STAT. The investigation includes scores of papers authored by four top scientists and institute leaders, including CEO Laurie Glimcher and COO William Hahn.

Hospitals 145
article thumbnail

PQA Releases Third Edition of Social Determinants of Health Resource Guide

Pharmacy Times

The third edition of the Pharmacy Quality Alliance resource guide includes 40 total SDOH services and 8 new services, as well as 10 initiative updates from the previous 2 editions.

148
148
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Former Pfizer statistician found guilty of insider trading on Paxlovid trial results

Fierce Pharma

A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.

144
144
article thumbnail

Feds bar Theranos founder Elizabeth Holmes from government health programs

STAT

WASHINGTON — Theranos founder and ex-CEO Elizabeth Holmes is banned from federal health programs for nine decades, the health department announced Friday. Holmes was sentenced in November 2022 to 11 years in prison following a trial that determined she knew her blood-testing startup, which was founded in 2003 and which claimed to be able to test for a range of diseases and risks with one finger prick, produced inaccurate and faulty results.

143
143

More Trending

article thumbnail

After row with Hungary and Poland, Pfizer sues Romania over missed COVID vaccine payments

Fierce Pharma

Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021.

Vaccines 128
article thumbnail

Looking Back to Go Forward: What 2023 Has Taught Us About Biosimilar Adoption

Pharmacy Times

In 2024, there is an urgent need for policies that will accelerate biosimilar use to achieve lower system-wide health care costs.

132
132
article thumbnail

Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset

Fierce Pharma

More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnose | More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients.

FDA 128
article thumbnail

Updating Hospital Policies to Improve Inpatient Care for Patients With Parkinson Disease

Pharmacy Times

Hospital pharmacists can play an important role in advocating for, designing, and implementing various policies to optimize care.

Hospitals 131
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Hospitals offer their custom-built tech for sale in search of new revenue streams

STAT

Hospitals aren’t usually in the business of selling technology tools. But that’s changing thanks to a collision of financial pressures and an explosion of new technology that could both improve patients’ health and ease the burden of administrative tasks on limited staff. At the J.P. Morgan Healthcare conference, an exclusive, invitation-only event for investors, several influential health systems like Mayo Clinic and Mass General Brigham doubled down on new revenue streams

Hospitals 127
article thumbnail

Lightfully Behavioral Health unveils virtual mental health program for higher ed students

Fierce Healthcare

Lightfully Behavioral Health, a hybrid mental health provider, has launched a new offering to support college students. | Lightfully U is intended to support the more than 60% of college students who have at least one mental health condition. The offering is a virtual intensive outpatient program targeted at college students ages 18 through 25 with higher-acuity conditions.

123
123
article thumbnail

FDA Grants Fast Track Designation to Avutometinib Plus Sotorasib for Treatment of NSCLC

Pharmacy Times

The treatment is for patients with KRAS G12C-mutant metastatic NSCLC who have previously received at least 1 systemic therapy and were not treated with a KRAS G12C inhibitor.

FDA 123
article thumbnail

STAT+: FDA scolds Novartis over a misleading TV ad for a breast cancer treatment

STAT

The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about a best-selling breast cancer treatment in a television ad in 2022. In a letter dated Thursday, the agency admonished the company for touting the benefits of its Kisqali medicine by referencing data that did not support the messages in the ad. In particular, the FDA cited an analysis of patient-reported outcomes data that had limitations and failed to demonstrate Kisqali “helps preserve

FDA 123
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Plant Protein Intake Linked to Disease Prevention, Healthy Aging Among Women

Drug Topics

Findings from the current study lend scientific credence to the idea that making informed dietary choices can help promote favorable health outcomes.

123
123
article thumbnail

Implementing USP Guidelines in Pediatric Hospitals

Pharmacy Times

Protecting this vulnerable patient population requires specially designed strategies.

Hospitals 120
article thumbnail

Intermountain-owned physician group to close if no buyer is found by March 29

Fierce Healthcare

Intermountain Health plans to shut down Saltzer Health, a multispecialty group the system acquired less than four years ago, if it’s unable to find a buyer by March 29, according to an announcement | Saltzer Health has more than 450 employees across 11 Idaho locations. It attributes its situation to "significant financial pressures," but said it is "optimistic" that at least some services could be sold to a new owner.

120
120
article thumbnail

AstraZeneca adds to rare blood disease portfolio with world-first Voydeya approval in Japan

Fierce Pharma

A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence in the disease area with a wo | The drug bolsters the company's portfolio in paroxysmal nocturnal haemoglobinuria (PNH) just as the market heats up thanks to new competitors from Novartis and Apellis.

119
119
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Employers are facing solution fatigue. UnitedHealthcare is launching a new resource hub to help

Fierce Healthcare

UnitedHealthcare is rolling out a new resource hub that seeks to make it easier for members to use wellness offerings while also easing the financial burden on employers. | UnitedHealthcare is rolling out a new resource hub that seeks to make it easier for members to use wellness offerings while also easing the financial burden on employers.

118
118
article thumbnail

AZ bags first approval for PNH therapy danicopan, in Japan

pharmaphorum

AstraZeneca gets its first approval for oral Factor D inhibitor danicopan, in Japan, for treatment of paroxysmal nocturnal haemoglobinuria

116
116
article thumbnail

Long-term care hospitals can't afford to treat their sickest Medicare patients, AHA says

Fierce Healthcare

Traditional Medicare’s bar for reimbursing long-term care hospitals (LTCH) for severely ill, “high-cost outlier” patients has spiked under current payment policies. | The cutoff for an expensive long-term care hospital case to qualify for greater reimbursement rose 55% from FY 2023 to FY 2024, and is projected to rise another 17% the following year, AHA wrote in a recent white paper calling for policymaker intervention.

Hospitals 116
article thumbnail

JP Morgan 2024 – Graham Heap

pharmaphorum

Learn more about Graham Heap, Takeda VP and the lead of TAK-279, in this exclusive live interview at JP Morgan in 2024. Gain insights into Heap's role, achievements, and the future of TAK-279.

115
115
article thumbnail

Watch DSN: CVS Health's Cara McNulty discusses suicide prevention, other critical mental health initiatives

Drug Store News

Cara McNulty, president, behavioral health and mental well-being, CVS Health, discusses the resources CVS Health has implemented to prevent suicides as well as programs to help people before or during a mental health crisis.

115
115
article thumbnail

CG Oncology lines up $180m IPO and a $1bn valuation

pharmaphorum

CG Oncology joins the queue of US biotech companies hoping to complete an IPO, aiming to raise $181m for its late-stage bladder cancer therapy.

111
111
article thumbnail

EMA Looks Back at Medicines Approved in 2023

BioPharm

The agency recommended 77 drugs for marketing authorization in 2023, including 39 new APIs.

110
110
article thumbnail

FDA allows Florida to import drugs from Canada

The Checkup by Singlecare

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted the state of Florida the authority to import certain prescription drugs from Canada—an important measure to counteract soaring prescription costs. It is the first time the FDA has authorized a state to import prescription medications from another country, which sets the precedent for more states and Indian tribes to follow suit.

FDA 105
article thumbnail

Redefining chronic disease management with novel digital solutions

pharmaphorum

Basel, Switzerland, is becoming an innovative biotech hub at the forefront of the digital revolution, proving fertile ground for a variety of start-ups in the healthcare space.

105
105
article thumbnail

Opinion: STAT+: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

STAT

What a week — this year’s might have been the busiest JPM I’ve ever had. I’m not saying that to brag, it’s a statement about the industry. There was even one tweet from STAT’s Adam Feuerstein calling the meeting mood “jubilant.” As a partner at an executive search firm, I’d concur. My time was packed with the usual mix of requests from potential, current, and former clients as well as investors to discuss search projects, and of cour

105
105
article thumbnail

FDA turns down Satsuma’s nasal migraine treatment

pharmaphorum

Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101. The drug – a new dry powder intranasal formulation of the well-established migraine therapy dihydroergotamine mesylate (DHE) – was submitted for approval in the US last March as an easy-to-use, portable treatment option for acute migraine attacks, with or without aura, in adult patients.

FDA 105
article thumbnail

Nutrabolt makes minority investment into Bloom Nutrition

Drug Store News

Nutrabolt will take an ownership stake of approximately 20% in Bloom Nutrition, which is part of a larger $90 million financing.

103
103
article thumbnail

How Financialization Has Impacted the US Healthcare System

Pharmaceutical Commerce

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

100
100
article thumbnail

IQVIA Predicts Biosimilar, Generic Competition Will Cost Originators $192 Billion by 2028

Drug Topics

According to IQVIA's most recent Global Use of Medicine report, losses for originator products are projected to rise by over $80 billion over the next 5 years due to market introductions of new biosimilar and generic drugs.

98
article thumbnail

Could novel antibiotic successfully treat a ‘priority 1 pathogen’?

European Pharmaceutical Review

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. Currently in Phase I development , the antibiotic’s novel mechanism of action was showcased through its effectiveness against the pathogen in in vitro studies.